臨床試驗

TMZ + RT + 5-ALA + LIDU SDT System for Newly Diagnosed Butterfly Glioma

NCT：NCT07862647 · RECRUITING

NCT IDNCT07862647

狀態RECRUITING

開始日期2026-10-29

完成時間2028-03-30

SponsorAlpheus Medical, Inc. (INDUSTRY)

First posted2026-10-07

Last updated2026-10-07

簡要摘要

This study is assessing the safety and tolerability of 5-ALA- mediated Porphyrin Metabolite Activation (PoMA) with LIDU ultrasound, in patients who have just been diagnosed with bihemispheric (in both sides of the brain) glioblastoma, sometimes called butterfly glioblastoma, before they complete their standard of care chemotherapy and radiation and after their standard of care chemotherapy and radiation while they are receviing their standard of care adjuvant chemotherapy.

官方來源

在 ClinicalTrials.gov 上查看 →

資料來自 ClinicalTrials.gov API。最新狀態請參閱官方紀錄。